纽约纪念斯隆凯特琳癌症中心的胃肠肿瘤服务部的首席主治医师Yelena Y Janjigian博士(该试验的主要研究者)表示：“尽管接受了以治愈为目的的化疗和手术，胃癌患者仍经常面临癌症复发以及预后不良的风险。MATTERHORN数据表明，包含度伐利尤单抗的围手术期联合治疗方案在临床意义上改善了患者结局，其中包括降低癌症复发的风险。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.